Asthma / Inhalers

DUOVA ROTACAPS are indicated in the maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease).

na

FORACORT Multi-haler is indicated in the regular treatment of asthma, where the use of a combination (long-acting, beta 2 -agonist and inhaled corticosteroid) has been found to be appropriate. They are also indicated in the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD), with a history of repeated exacerbations despite regular therapy with long-acting bronchodilators.

FORACORT Rotacaps are indicated in the regular treatment of asthma, where the use of a combination (long-acting, beta 2 -agonist and inhaled corticosteroid) has been found to be appropriate. They are also indicated in the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD), with a history of repeated exacerbations despite regular therapy with long-acting bronchodilators.

FORACORT Rotacaps are indicated in the regular treatment of asthma, where the use of a combination (long-acting, beta 2 -agonist and inhaled corticosteroid) has been found to be appropriate. They are also indicated in the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD), with a history of repeated exacerbations despite regular therapy with long-acting bronchodilators.

FORATEC are indicated in the treatment of patients with asthma (including nocturnal asthma and the prevention of exercise-induced bronchospasm), and COPD requiring long-term regular bronchodilator therapy. Such patients should also be receiving regular and adequate doses of inhaled anti-inflammatory agents.

For the treatment of chronic reversible airways obstruction, particularly in chronic bronchitis and asthma.

LEVOLIN Respules are indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children (6–11 years old) with reversible obstructive airway disease.

Revolizer is a novel DPI device, which is the result of a design and development programme to address the critical requirements of an ideal inhalation device. It provides accurate dosing and greater lung deposition even at low inspiratory flow rates combined with ease of use. It provides an improved respirable fraction while adding style and modern design to give patients a revolution in inhalation therapy.

Revolizer  is an extremely simple device. The user has to open the device, insert the rotacap, shut the device and then inhale.

The world`s first transparent Rotahaler is a dry powder inhaler (DPI). Rotahaler is used with Rotacaps, which is premetered single dose medication for inhalation. DPI`s are breath-actuated devices and eliminate the need for co-ordination of actuation and inspiration. DPI`s are emerging as cost-effective, simple-to-use and environmentally preferred devices for pulmonary drug delivery.

na

na

TIOVA Inhaler is indicated in the maintenance treatment of COPD.

The recommended dosage of tiotropium bromide is 2 puffs of TIOVA Inhaler once daily.

TIOVA is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.

The recommended dosage of TIOVA is one Rotacap inhaled once daily, using the Cipla Rotahaler/ Revolizer.

No dosage adjustment is required for geriatric, hepatically-impaired, or renally-impaired patients. However, patients with moderate to severe renal impairment, who are being treated with TIOVA should be monitored closely.

TIOVA are for inhalation only and must not be swallowed.

na